Janux’s prostate cancer immunotherapy’s response rate drops, according to new early-stage datanews2025-12-01T21:10:17+00:00December 1st, 2025|Endpoints News|
FDA and Prasad’s Covid vaccine death claims lack key detailsnews2025-12-01T20:24:17+00:00December 1st, 2025|Endpoints News|
Belite Bio aims for first approval of Stargardt disease treatment with Phase 3 successnews2025-12-01T18:22:00+00:00December 1st, 2025|Endpoints News|
UK to spend more on medicines for US tariff exemptionnews2025-12-01T16:28:20+00:00December 1st, 2025|Endpoints News|
Angelini, European Investment Bank join forces; Radiopharma startup raises $40Mnews2025-12-01T16:00:23+00:00December 1st, 2025|Endpoints News|
Lilly slightly lowers self-pay prices for single-dose vials of Zepboundnews2025-12-01T14:37:47+00:00December 1st, 2025|Endpoints News|
“Heavy AI” is taking over biopharma | Signal Pulse Reportnews2025-12-01T13:53:30+00:00December 1st, 2025|Endpoints News|
Introducing Endpoints Signal — intelligence for fresh biopharma insightsnews2025-12-01T13:53:11+00:00December 1st, 2025|Endpoints News|
Gene writing startup Tessera strikes $150M partnership with Regeneronnews2025-12-01T12:00:18+00:00December 1st, 2025|Endpoints News|
